Transgene, AstraZeneca enter into a collaboration for Invir.IO based armed oncolytic immunotherapies
Innovative oncolytic viruses resulting from this collaboration will use Transgene’s proprietary next generation viral platform Invir.IO. Under the terms of the agreement Transgene will contribute its oncolytic virus